ADMA Biologics, Inc. - 8-K Filing Summary
Business Context and Reporting Period
This Form 8-K was filed by ADMA Biologics, Inc. on February 21, 2025, reporting events that occurred on February 19, 2025. The filing details executive and director compensation decisions approved by the Board of Directors upon the recommendation of the Compensation Committee.
Key Financial Metrics
The filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on compensation arrangements.
Material Changes and Compensation Details
The Board approved the following compensation for key executive officers effective for the 2025 fiscal year and reflecting 2024 performance:
- Adam S. Grossman (President & CEO): 2025 Base Salary of $925,000; 2024 Non-Equity Incentive Compensation of $1,020,000; 252,022 RSUs; 376,744 Stock Options.
- Kaitlin Kestenberg (COO & SVP Compliance): 2025 Base Salary of $575,000; 2024 Non-Equity Incentive Compensation of $293,625; 77,784 RSUs; 116,279 Stock Options.
- Brad Tade (CFO & Treasurer): 2025 Base Salary of $500,000; 2024 Non-Equity Incentive Compensation of $254,475; 62,227 RSUs; 93,023 Stock Options.
Equity Terms: The stock options have an exercise price of $16.07 per share, based on the closing price on the grant date. RSUs vest quarterly over four years. Options vest 25% after one year and the remainder monthly over the subsequent three years.
Director Compensation Changes:
- Non-employee directors will receive annual equity grants valued at $350,000 (split 50% RSUs, 50% options).
- Committee retainers increased effective January 1, 2025 (e.g., Audit Committee Chair retainer set at $25,000).
- Annual cash retainer for non-employee directors remains $50,000.
Guidance, Outlook, and Risks
The filing does not provide financial guidance, outlook, or discuss specific risks or contingencies beyond standard compensation disclosures. The cash bonuses for executives are scheduled for payment in early March 2025.
Investor Verification Checklist
- Verify the impact of the $16.07 option exercise price relative to current market trading prices.
- Confirm the total dilution impact of the 502,033 new RSUs and 586,046 new stock options granted to executives.
- Review the 2024 corporate goals and milestones that triggered the $1.57 million in total non-equity cash bonuses for the three executives.
- Assess the increase in director compensation costs due to the new $350,000 annual equity grant policy and committee retainer adjustments.